Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENICA ALZHEIMER'S TEST DEMONSTRATES 95% SENSITIVITY

This article was originally published in The Gray Sheet

Executive Summary

GENICA ALZHEIMER'S TEST DEMONSTRATES 95% SENSITIVITY and 94% specificity in identifying patients with the disease in a study led by Leonard Scinto, Brigham and Women's Hospital, Boston, et al., the results of which were published in the Nov. 11 issue of Science. The test involves placing diluted drops of the drug tropicamide in patients' eyes and then measuring pupil dilation with a pupillometer. The test is considered positive if patients exhibit hypersensitivity in their pupil dilation response to the drug.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel